Innovate Biopharmaceuticals (INNT) & Its Rivals Head to Head Contrast

Innovate Biopharmaceuticals (NASDAQ: INNT) is one of 553 public companies in the “Pharmaceutical preparations” industry, but how does it contrast to its rivals? We will compare Innovate Biopharmaceuticals to similar businesses based on the strength of its institutional ownership, dividends, earnings, risk, valuation, analyst recommendations and profitability.

Risk & Volatility

Innovate Biopharmaceuticals has a beta of -3.63, suggesting that its stock price is 463% less volatile than the S&P 500. Comparatively, Innovate Biopharmaceuticals’ rivals have a beta of 1.33, suggesting that their average stock price is 33% more volatile than the S&P 500.

Earnings and Valuation

This table compares Innovate Biopharmaceuticals and its rivals gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Innovate Biopharmaceuticals $4.07 million -$24.16 million N/A
Innovate Biopharmaceuticals Competitors $2.14 billion $226.59 million -3.52

Innovate Biopharmaceuticals’ rivals have higher revenue and earnings than Innovate Biopharmaceuticals.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Innovate Biopharmaceuticals and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Innovate Biopharmaceuticals 0 0 2 0 3.00
Innovate Biopharmaceuticals Competitors 4682 13296 28040 1007 2.54

Innovate Biopharmaceuticals currently has a consensus price target of $35.00, suggesting a potential upside of 2,101.26%. As a group, “Pharmaceutical preparations” companies have a potential upside of 59.49%. Given Innovate Biopharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Innovate Biopharmaceuticals is more favorable than its rivals.

Insider & Institutional Ownership

10.3% of Innovate Biopharmaceuticals shares are owned by institutional investors. Comparatively, 45.8% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 17.1% of Innovate Biopharmaceuticals shares are owned by company insiders. Comparatively, 15.6% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Innovate Biopharmaceuticals and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Innovate Biopharmaceuticals N/A -1,207.69% -245.78%
Innovate Biopharmaceuticals Competitors -1,775.73% -94.19% -27.76%

Summary

Innovate Biopharmaceuticals rivals beat Innovate Biopharmaceuticals on 7 of the 12 factors compared.

Innovate Biopharmaceuticals Company Profile

Innovate Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company's lead product candidate is INN-202 that has completed Phase IIb clinical trial for the treatment of celiac disease. It also develops INN-108, which has completed Phase I clinical trial to treat mild-to-moderate ulcerative colitis; INN-217 for the treatment of non-alcoholic steatohepatitis and microbiome; and INN-289 to treat crohn's disease, as well as product for the treatment of alcoholic steatohepatitis (ASH). In addition, the company holds rights for INN-329, a formulation of secretin that is used to enhance visualization in magnetic resonance cholangiopancreatography procedures that is in Phase III clinical trial. The company has a research collaboration with Massachusetts General Hospital for the treatment of ASH. Innovate Biopharmaceuticals, Inc. is based in Raleigh, North Carolina.

Receive News & Ratings for Innovate Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovate Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.